Clinical Trials Logo

Clinical Trial Summary

Our aim is to compare outcomes of patients with benzodiazepine-refractory alcohol withdrawal syndrome who are treated with either a phenobarbital-based or a lorazepam based protocol.


Clinical Trial Description

- This study is a prospective, open-label, randomized, controlled trial.

- The electronic medical record will be used to identify patients who have a diagnosis of alcohol withdrawal or are receiving alcohol withdrawal. Subjects who are anticipated to meet inclusion criteria will be pre-consented for the study using an informed consent process. see informed consent form.

- Subjects will not be enrolled and randomized until they have met inclusion criteria.

- If a patient meets criteria, but is deemed non-decisional or unable to give consent, the patient's medical decision maker will undergo the informed consent process.

- After enrollment, participants will be randomized to either the control group (lorazepam-based therapy) or the study group (phenobarbital-based therapy)

- Personnel unassociated with patient screening, enrollment, or follow up will create the allocation sequence and will use a random, computerized number generator. The allocation sequence will then be transferred to sequentially numbered, opaque envelopes for purposes of allocation concealment. These sequentially numbered envelopes, which are blinded to clinical trial coordinators/physicians, will be handed out in order as patients are enrolled. Clinical trial coordinators/physicians will verify treatment eligibility and informed consent before opening the envelope to obtain the treatment assignment.

- The study group will be placed on the phenobarbital-based protocol as described below in procedures. The control group will be placed on the lorazepam-based protocol, also listed below in procedures.

- All medications in the study are FDA approved. No investigational medicines will be used.

- Data will be collected on each participant as noted below in measurements.

- The data will be analyzed and published as noted above in the statistical analysis plan and data use and management section. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04156464
Study type Interventional
Source OSF Healthcare System
Contact Rachael M Davis, MD
Phone 309-655-7257
Email rachael.m.davis@osfhealthcare.org
Status Recruiting
Phase Phase 4
Start date July 6, 2020
Completion date March 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03916939 - Osteopathic Treatment to Alcohol Withdrawal Syndrome N/A
Completed NCT04858490 - Remote Treatment of Alcohol Withdrawal N/A
Not yet recruiting NCT04997330 - Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction N/A
Recruiting NCT04876443 - Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
Completed NCT05131334 - Auricular Vagal Stimulation in Alcohol Craving N/A
Completed NCT02349477 - Gabapentin for Alcohol Relapse Prevention Phase 2
Terminated NCT01937364 - Preventing Alcohol Withdrawal With Oral Baclofen Phase 2
Completed NCT05393544 - Digitally Assisted Recovery Coach N/A
Completed NCT00523185 - A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal N/A
Completed NCT01573052 - Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Phase 4
Enrolling by invitation NCT06173973 - Effects of Ketone Supplementation on Acute Alcohol Withdrawal Phase 2/Phase 3
Active, not recruiting NCT03737864 - NCARE, Transition to Recovery N/A
Recruiting NCT03878225 - Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans? N/A
Terminated NCT03586089 - Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome N/A
Completed NCT02202148 - Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal N/A
Completed NCT02251912 - Oxytocin Treatment of Alcohol Dependence Phase 2
Completed NCT01212185 - Oxytocin Treatment of Alcohol Withdrawal Phase 1
Recruiting NCT04793685 - Prazosin for Alcohol Use Disorder With Withdrawal Symptoms Phase 1/Phase 2
Withdrawn NCT04159909 - Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal N/A
Completed NCT05563350 - Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms